News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

12 October 2017 CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same

CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA) Hands-Only™ cardiopulmonary resuscitation (CPR) training to employees.

> Read More
28 September 2017 Japan’s Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment

Global biotherapeutics leader CSL Behring today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved AFSTYLA® (hereafter AFSTYLA) [lonoctocog alfa] a recombinant single-chain coagulation factor VIII (rVIII-SingleChain) in patients with haemophilia A (congenital factor VIII deficiency).

> Read More
28 September 2017 Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders

The Great Lakes Hemophilia Foundation (GLHF), the New York City Hemophilia Chapter (NYCHC) and the Ohio Bleeding Disorders Council (OBDC) take on complex legislative and public policy issues to ensure patients’ voices are heard in their statehouses.

> Read More
19 September 2017 CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State

Penn State today announced that CSL Behring has committed $4.92 million to Penn State over the next six years to create the multidisciplinary Center of Excellence in Biotechnology, and to revitalize the Shared Fermentation Facility.

> Read More
14 September 2017 CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI

Immunoglobulin Leader Donates €15,000 to IPOPI International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives.

> Read More
Page 1 of 7 Next | Last

LinkedIn Twitter Facebook Google+